Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jaguar Health Inc
(NQ:
JAGX
)
1.170
-0.060 (-4.88%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Jaguar Health Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Jaguar Health to Host Investor Webcast Monday, November 15th at 8:30 AM Eastern Time Regarding Q3 2021 Financials & Business Updates
November 10, 2021
Click here to register for webcast Company plans to file Q3 2021 10-Q on November 15, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer
November 08, 2021
SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the appointment by Napo EU S.p.A., the company's Italian subsidiary, of Annabella Amatulli as chief...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Jaguar Health Completes Filing of New Animal Drug Application for Conditional Approval of Canalevia-CA1 (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs, Clearing Way for December 2021 Launch
November 02, 2021
Canalevia™-CA1 is the first and only oral plant-based prescription drug candidate for CID in dogs Jaguar kicks off educational awareness contest in honor of International Jaguar Day; Click here to...
From
Jaguar Health, Inc.
Via
AccessWire
The Merger of Dragon SPAC S.p.A. and Napo EU S.p.A. has Closed
November 01, 2021
The combined entity is named Napo EU S.p.A. SAN FRANCISCO, CA / ACCESSWIRE / November 1, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the merger of its Italian subsidiary Napo EU...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 29, 2021
SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that, effective October 25, 2021, the Company granted nonstatutory...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Italian Government Clears Merger Plan of Dragon SPAC S.p.A. and Jaguar Health's Italian Subsidiary Napo EU S.p.A. for Closing
October 25, 2021
Merger expected to be effective within a week The combined entity will be named Napo EU S.p.A. Merger effects the exclusive license agreement between Jaguar and Napo EU S.p.A. including up-front...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A.
October 07, 2021
Dragon SPAC and Jaguar subsidiary Napo EU submit required notification to the Italian government in support of consummating the merger Results accepted for third-party, investigator-initiated Phase 2...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health's Founder and CEO Lisa Conte to Be Honored with Pure Earth Impact Award
September 30, 2021
Award celebrates Ms. Conte's 30-year, unrelenting commitment to supporting Indigenous communities in the Amazon and responsibly harvesting and commercializing the first-ever plant-based oral medicine...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Death
Exposures
Death
Product Safety
Jaguar Health Announces that Ladenburg Thalmann is Hosting R&D Showcase Webinar About Cancer Therapy-related Diarrhea on September 29, 2021
September 27, 2021
Leading oncologists discuss importance of supportive care for cancer patients to address debilitating diarrhea resulting from cancer therapy Virtual event 1:00 PM to 2:10 PM Eastern Registration open...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in Dogs
September 23, 2021
Jaguar planning for launch of Canalevia™ for CID in dogs this December Canalevia is the first and only oral plant-based prescription drug candidate for CID in dogs SAN FRANCISCO, CA / ACCESSWIRE /...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern Time
September 16, 2021
Click here to register for webcast Jaguar kicks off educational awareness contest in honor of Indigenous Peoples' Day; Click here to enter SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2021 / Jaguar...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines Agency
September 15, 2021
The conditional marketing authorization pathway in Europe for crofelemer for this orphan disease is the initial focus of Napo EU under the license agreement between Napo EU and Napo Pharmaceuticals...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces Closing of Private Placement Priced at a Premium to Market
September 14, 2021
Participating investors include Jaguar CEO and CFO, Dragon SPAC S.p.A. sponsor Josh Mailman, and plant-based pharmaceutical manufacturing pioneer Indena S.p.A. Company to host investor webcast Monday,...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Jaguar Health Appoints Karen Brunke, Ph.D. as Corporate and Business Development EVP and Chip Whitlow as Animal Health Products Marketing Director
September 09, 2021
Appointments represent Jaguar's focus on forging business development partnerships to advance crofelemer development and access and preparing for the expected near-term approval and commercialization...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health, Inc. Announces 1-for-3 Reverse Stock Split
September 03, 2021
- Reverse split approved by majority of common stock shareholders at December 2020 special meeting of stockholders - Shares of Jaguar common stock to begin trading on split-adjusted basis on September...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Jaguar Health Reports Voting Results from 2021 Annual Meeting of Stockholders
September 03, 2021
Proposals 1, 2, 4, 5 & 6 approved SAN FRANCISCO, CA / ACCESSWIRE / September 3, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Jaguar Health Subsidiary Napo Pharmaceuticals Submits Late-Breaking Abstract for Consideration for Presentation at the 2021 IDWeek Annual Meeting
August 23, 2021
Exploratory study evaluating effects of crofelemer on gut microbiome SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Napo Pharmaceuticals, the wholly-owned subsidiary of Jaguar Health, Inc....
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe
August 19, 2021
Per the terms of the agreement, Napo Pharmaceuticals will receive an upfront payment of $10 million payable in two installments following the anticipated merger of Napo EU and Dragon SPAC S.p.A. and is...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Subsidiary Announces Completion of Additional Preclinical Study of Lechlemer (NP-300), the Company's Human Drug Product Candidate for Diarrhea Relief from Cholera and Other Acute Infectious Diarrhea
August 17, 2021
In support of planned Investigational New Drug application for lechlemer, Napo Pharmaceuticals, Jaguar's wholly owned subsidiary, received comprehensive animal toxicity preclinical services supported...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Death
Exposures
Death
Product Safety
Jaguar Health, Inc. Reports 2021 Second Quarter Financial Results
August 13, 2021
Second quarter 2021 Mytesi® net and gross sales were approximately $0.4 million and approximately $4.9 million Company transitioning to primarily selling Mytesi directly through selected specialty...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
Jaguar Health Announces Time Change for Friday, August 13th Investor Webcast to 8:00 AM Eastern Time
August 10, 2021
Registration link for webcast appears below Company plans to file Q2 2021 10-Q on August 13, 2021 SAN FRANCISCO, CA / ACCESSWIRE / August 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health to Host Investor Webcast Friday, August 13th at 8:30 AM Eastern Time Regarding Q2 2021 Financials & Business Updates
August 10, 2021
- Registration link for webcast appears below - Company plans to file Q2 2021 10-Q on August 13, 2021 - Jaguar kicks off educational awareness contest in honor of African Traditional Medicine Day SAN...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote
August 06, 2021
Based on a preliminary review of votes cast, over 75% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene September 3, 2021 at 8:30 AM Pacific Standard Time to provide time to...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Interview with Lisa Conte to Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates
July 28, 2021
Registration link for webcast appears below SAN FRANCISCO, CA / ACCESSWIRE / July 28, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) issued a reminder today that an Innovators with Jane King interview of...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces that Innovators with Jane King Interview with Lisa Conte will Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates
July 26, 2021
Registration link for webcast appears below SAN FRANCISCO, CA / ACCESSWIRE / July 26, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) announced today that an Innovators with Jane King interview of Lisa Conte,...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 23, 2021
SAN FRANCISCO, CA / ACCESSWIRE / July 23, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') announced today that effective July 15, 2021, the Company granted nonstatutory stock...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Napo EU S.p.A., Jaguar Health's Italian Subsidiary, and Dragon SPAC S.p.A. Announce Close of 8,830,000 Euro Dragon SPAC Financing
July 19, 2021
Napo EU, the identified target of Dragon SPAC, seeks to develop plant-based crofelemer to potentially treat orphan disease - short bowel syndrome (crofelemer has received orphan-drug designation from...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces Completion of Investigator-Initiated Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients
July 14, 2021
Abstract of study results submitted by the third-party investigators to December 2021 San Antonio Breast Cancer Symposium SAN FRANCISCO, CA / ACCESSWIRE / July 14, 2021 / Jaguar Health, Inc....
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, August 6, 2021 and Encourages All Shareholders to Vote
July 09, 2021
Based on a preliminary review of votes cast, over 74% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene August 6, 2021 at 8:30 AM Pacific Standard Time to provide time to...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Jaguar Health Set to Join Russell Microcap Index
June 23, 2021
Jaguar kicks off educational awareness contest about medicinal plants SAN FRANCISCO, CA / ACCESSWIRE / June 23, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Derivatives
Exposures
Derivatives
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.